Home   Search   Browse   Statistics   User guide   FAQs   Post question   Download   Process data  
Search results for the GEO ID: GSE14386
(Click on the check boxes provided under "Select for analysis", to initiate grouping)
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)
GSM ID
GPL ID
Select for analysis
Title
Source name
Description
Characteristics
GSM359574
GPL570
CIS patient No.1_Untreated PBMCs from No.1 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359575
GPL570
CIS patient No.2_Untreated PBMCs from No.2 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359576
GPL570
CIS patient No.3_Untreated PBMCs from No.3 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359577
GPL570
CIS patient No.4_Untreated PBMCs from No.4 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359578
GPL570
CIS patient No.5_Untreated PBMCs from No.5 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359579
GPL570
CIS patient No.6_Untreated PBMCs from No.6 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359580
GPL570
CIS patient No.7_Untreated PBMCs from No.7 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359581
GPL570
CIS patient No.8_Untreated PBMCs from No.8 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359582
GPL570
CIS patient No.9_Untreated PBMCs from No.9 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359583
GPL570
CIS patient No.10_Untreated PBMCs from No.10 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359584
GPL570
CIS patient No.11_Untreated PBMCs from No.11 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359585
GPL570
CIS patient No.12_Untreated PBMCs from No.12 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359586
GPL570
CIS patient No.13_Untreated PBMCs from No.13 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359587
GPL570
CIS patient No.14_Untreated PBMCs from No.14 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359588
GPL570
CIS patient No.15_Untreated PBMCs from No.15 CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in absence of IFNb-1a
GSM359589
GPL570
CIS patient No.1_Treated PBMCs from No.1 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359590
GPL570
CIS patient No.2_Treated PBMCs from No.2 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359591
GPL570
CIS patient No.3_Treated PBMCs from No.3 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359592
GPL570
CIS patient No.4_Treated PBMCs from No.4 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359593
GPL570
CIS patient No.5_Treated PBMCs from No.5 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359594
GPL570
CIS patient No.6_Treated PBMCs from No.6 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359595
GPL570
CIS patient No.7_Treated PBMCs from No.7 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359596
GPL570
CIS patient No.8_Treated PBMCs from No.8 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359597
GPL570
CIS patient No.9_Treated PBMCs from No.9 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359598
GPL570
CIS patient No.10_Treated PBMCs from No.10 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359599
GPL570
CIS patient No.11_Treated PBMCs from No.11 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359600
GPL570
CIS patient No.12_Treated PBMCs from No.12 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359601
GPL570
CIS patient No.13_Treated PBMCs from No.13 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359602
GPL570
CIS patient No.14_Treated PBMCs from No.14 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
GSM359603
GPL570
CIS patient No.15_Treated PBMCs from No.15 CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a 107 PBMCs per condition derived from 15 CIS patients were stimulated with plate-immobilized αCD3 (1 μg/ml) and αCD28 (5 μg/ml) mAb (BD Biosciences) in the absence or presence of IFNβ-1a (1000 U/ml) (EMD Serono Inc) for 24 h in serum-free medium (Gibco). Gene expression of PBMCs from CIS patient stimulated with aCD3+aCD28 mAb for 24h in presence of IFNb-1a
 
 
Make groups for comparisons
(2 groups will be compared at a time)
Select GSMs and click on "Add groups"
Enter the group name here:


Select expression type
Transcripts profile based on;
A. Differential status (Up/Down regulation)
B. Absolute calls (Transcribed/Not-detected)
 
Filter results by number of probes